CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 50 of 219 entries

View as:

Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02072278 Org: User:

Start: 02/28/14 End: - Due: -

MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

Phase: N/A Priority: Normal

NCT ID: NCT00266344 Org: User:

Start: 11/30/05 End: 10/31/06 Due: 10/31/07

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

Phase: N/A Priority: Normal

NCT ID: NCT02093169 Org: User:

Start: 02/28/14 End: - Due: -

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

Phase: N/A Priority: Normal

NCT ID: NCT00771134 Org: User:

Start: 12/31/08 End: 08/31/09 Due: 08/31/10

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Phase: N/A Priority: Normal

NCT ID: NCT02649608 Org: User:

Start: 01/31/16 End: 12/31/16 Due: 12/31/17

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT04104503 Org: User:

Start: 09/17/19 End: 04/09/20 Due: 04/09/21

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

Phase: N/A Priority: Normal

NCT ID: NCT03766867 Org: User:

Start: 12/03/18 End: 08/28/19 Due: 08/28/20

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Phase: N/A Priority: Normal

NCT ID: NCT01571453 Org: User:

Start: 05/31/12 End: - Due: -

Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women

Phase: N/A Priority: Normal

NCT ID: NCT02112903 Org: User:

Start: 04/30/14 End: - Due: -

Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01975779 Org: User:

Start: 07/31/13 End: - Due: -

Real World Effectiveness of Eptinezumab in Participants With Migraine

Phase: N/A Priority: Normal

NCT ID: NCT05284019 Org: User:

Start: 03/04/22 End: 04/14/23 Due: 04/14/24

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT02202226 Org: User:

Start: 01/31/13 End: - Due: -

Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes

Phase: N/A Priority: Normal

NCT ID: NCT00596817 Org: User:

Start: 12/31/07 End: 10/31/09 Due: 10/31/10

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT03189615 Org: User:

Start: 05/14/17 End: 04/23/18 Due: 04/23/19

Escitalopram in Patients With Generalized Anxiety Disorder

Phase: N/A Priority: Normal

NCT ID: NCT00902564 Org: User:

Start: 03/31/09 End: 03/31/10 Due: 03/31/11

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Phase: N/A Priority: Normal

NCT ID: NCT00694304 Org: User:

Start: 05/31/08 End: 04/30/10 Due: 04/30/11

A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT03884491 Org: User:

Start: 03/18/19 End: 07/22/19 Due: 07/22/20

Efficacy of Bifeprunox in Patients With Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT00704509 Org: User:

Start: 06/30/08 End: 11/30/09 Due: 11/30/10

Bioequivalence Study of Idalopirdine Tablets 60 mg

Phase: N/A Priority: Normal

NCT ID: NCT02371707 Org: User:

Start: 03/31/15 End: 04/30/15 Due: 04/30/16

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Phase: N/A Priority: Normal

NCT ID: NCT03668405 Org: User:

Start: 06/26/18 End: 05/27/19 Due: 05/27/20

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Phase: N/A Priority: Normal

NCT ID: NCT02006641 Org: User:

Start: 02/28/14 End: 12/31/16 Due: 12/31/17

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

Phase: N/A Priority: Normal

NCT ID: NCT01944969 Org: User:

Start: 10/31/13 End: 05/31/14 Due: 05/31/15

Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT04322227 Org: User:

Start: 01/23/20 End: 05/30/20 Due: 05/30/21

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT01377233 Org: User:

Start: 07/31/11 End: - Due: -

Eptinezumab in Participants With Episodic Cluster Headache

Phase: N/A Priority: Normal

NCT ID: NCT04688775 Org: User:

Start: 12/23/20 End: 10/05/23 Due: 10/05/24

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects	NCT02072278	H. Lundbeck A/S	user2@example.com	None	2014-02-28	-	-	-	-	2025-07-14
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)	NCT00266344	H. Lundbeck A/S	user2@example.com	None	2005-11-30	2006-10-31	2007-10-31	-	-	2025-07-14
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound	NCT02093169	H. Lundbeck A/S	user2@example.com	None	2014-02-28	-	-	-	-	2025-07-14
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression	NCT00771134	H. Lundbeck A/S	user2@example.com	None	2008-12-31	2009-08-31	2010-08-31	-	-	2025-07-14
An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients	NCT02649608	H. Lundbeck A/S	user2@example.com	None	2016-01-31	2016-12-31	2017-12-31	-	-	2025-07-14
A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects	NCT04104503	H. Lundbeck A/S	user2@example.com	None	2019-09-17	2020-04-09	2021-04-09	-	-	2025-07-14
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression	NCT03766867	H. Lundbeck A/S	user2@example.com	None	2018-12-03	2019-08-28	2020-08-28	-	-	2025-07-14
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries	NCT01571453	H. Lundbeck A/S	user2@example.com	None	2012-05-31	-	-	-	-	2025-07-14
Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women	NCT02112903	H. Lundbeck A/S	user2@example.com	None	2014-04-30	-	-	-	-	2025-07-14
Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects	NCT01975779	H. Lundbeck A/S	user2@example.com	None	2013-07-31	-	-	-	-	2025-07-14
Real World Effectiveness of Eptinezumab in Participants With Migraine	NCT05284019	H. Lundbeck A/S	user2@example.com	None	2022-03-04	2023-04-14	2024-04-14	-	-	2025-07-14
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia	NCT02202226	H. Lundbeck A/S	user2@example.com	None	2013-01-31	-	-	-	-	2025-07-14
Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes	NCT00596817	H. Lundbeck A/S	user2@example.com	None	2007-12-31	2009-10-31	2010-10-31	-	-	2025-07-14
Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects	NCT03189615	H. Lundbeck A/S	user2@example.com	None	2017-05-14	2018-04-23	2019-04-23	-	-	2025-07-14
Escitalopram in Patients With Generalized Anxiety Disorder	NCT00902564	H. Lundbeck A/S	user2@example.com	None	2009-03-31	2010-03-31	2011-03-31	-	-	2025-07-14
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults	NCT00694304	H. Lundbeck A/S	user2@example.com	None	2008-05-31	2010-04-30	2011-04-30	-	-	2025-07-14
A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects	NCT03884491	H. Lundbeck A/S	user2@example.com	None	2019-03-18	2019-07-22	2020-07-22	-	-	2025-07-14
Efficacy of Bifeprunox in Patients With Schizophrenia	NCT00704509	H. Lundbeck A/S	user2@example.com	None	2008-06-30	2009-11-30	2010-11-30	-	-	2025-07-14
Bioequivalence Study of Idalopirdine Tablets 60 mg	NCT02371707	H. Lundbeck A/S	user2@example.com	None	2015-03-31	2015-04-30	2016-04-30	-	-	2025-07-14
A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)	NCT03668405	H. Lundbeck A/S	user2@example.com	None	2018-06-26	2019-05-27	2020-05-27	-	-	2025-07-14
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil	NCT02006641	H. Lundbeck A/S	user2@example.com	None	2014-02-28	2016-12-31	2017-12-31	-	-	2025-07-14
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder	NCT01944969	H. Lundbeck A/S	user2@example.com	None	2013-10-31	2014-05-31	2015-05-31	-	-	2025-07-14
Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects	NCT04322227	H. Lundbeck A/S	user2@example.com	None	2020-01-23	2020-05-30	2021-05-30	-	-	2025-07-14
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia	NCT01377233	H. Lundbeck A/S	user2@example.com	None	2011-07-31	-	-	-	-	2025-07-14
Eptinezumab in Participants With Episodic Cluster Headache	NCT04688775	H. Lundbeck A/S	user2@example.com	None	2020-12-23	2023-10-05	2024-10-05	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance